429 related articles for article (PubMed ID: 1736014)
1. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
2. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score.
Aul C; Gattermann N; Germing U; Runde V; Heyll A; Schneider W
Leukemia; 1994 Nov; 8(11):1906-13. PubMed ID: 7967735
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
5. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
[TBL] [Abstract][Full Text] [Related]
6. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
7. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
8. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
Breccia M; Mengarelli A; Mancini M; Biondo F; Gentilini F; Latagliata R; Mandelli F; Alimena G
Leuk Res; 2005 Jul; 29(7):749-54. PubMed ID: 15927670
[TBL] [Abstract][Full Text] [Related]
10. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
[TBL] [Abstract][Full Text] [Related]
11. Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System.
Mirza I; Garzón R; Burns J; Edwards L; Fernandez-Cymering C; Kloss R
Conn Med; 2001 Aug; 65(8):455-63. PubMed ID: 11550445
[TBL] [Abstract][Full Text] [Related]
12. [Prediction of survival in myelodysplastic syndrome. Analysis of 2 scoring systems with prognostic value].
Sanz GF; Sanz MA; Vallespí T; Cañizo MC; García S; Torrabadella M; San Miguel JF; Irriguible D
Sangre (Barc); 1989 Feb; 34(1):41-6. PubMed ID: 2711284
[TBL] [Abstract][Full Text] [Related]
13. Serum deoxythymidine kinase in myelodysplastic syndromes.
Aul C; Gattermann N; Germing U; Winkelmann M; Heyll A; Runde V; Schneider W
Cancer; 1994 Jan; 73(2):322-7. PubMed ID: 8293395
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
15. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome.
Lee JH; Lee JH; Shin YR; Lee JS; Kim WK; Chi HS; Park CJ; Seo EJ; Lee KH
Leukemia; 2003 Feb; 17(2):305-13. PubMed ID: 12592327
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome.
Shih LY; Chiu WF; Lee CT
Leukemia; 1991 Dec; 5(12):1092-8. PubMed ID: 1774958
[TBL] [Abstract][Full Text] [Related]
17. [The prognostic significance of serum thymidine kinase in the myelodysplastic syndrome].
Aul C; Germing U; Gattermann N; Söhngen D; Heyll A
Dtsch Med Wochenschr; 1996 Sep; 121(37):1113-8. PubMed ID: 8925725
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.
Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
Leukemia; 1993 Apr; 7(4):499-508. PubMed ID: 8464227
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
[TBL] [Abstract][Full Text] [Related]
20. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
